Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population-Reference-Cited by-同舟云学术

Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population

Published:2013-05-02 Issue:7 Volume:29 Page:678-682
ISSN:0951-3590
Container-title:Gynecological Endocrinology
language:en
Short-container-title:Gynecological Endocrinology

Author:

Villa Paola,Moruzzi Maria C.,Lassandro Anna P.,Leoni Fulvio,Di Nardo Francesco,De Waure Chiara,Scambia Giovanni,

Publisher

Informa UK Limited

Subject

Obstetrics and Gynecology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.tandfonline.com/doi/pdf/10.3109/09513590.2013.788631

Reference25 articles.

1. Osteoporosis Prevention, Diagnosis, and Therapy

2. American Association of Clinical Endocrinologists Medical Guidelines For Clinical Practice For The Prevention and Treatment of Postmenopausal Osteoporosis: 2001 Edition, With Selected Updates For 2003

3. Office of the Surgeon General. Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: Department of Health and Human Services; 2004:436

4. Glucocorticoid-induced osteoporosis: an update

5. Perspectives on glucocorticoid-induced osteoporosis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucocorticoid-induced osteoporosis—from molecular mechanism to clinical practice;Drugs & Therapy Perspectives;2024-07-18

2. Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial;Bone;2021-05

3. The Association between Short Inter-Pregnancy Interval and Postmenopausal Osteoporosis, Saudi Arabia, Taif City, 2019: A case-control study;WORLD FAM MED;2021

4. Prevalence of bone mineral density loss and potential risk factors for osteopenia and osteoporosis in rheumatic patients in China: logistic regression and random forest analysis;Annals of Translational Medicine;2020-03

5. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force;Annals of the Rheumatic Diseases;2016-03-01